TSTickerStarGet alerts

Tvardi Therapeutics Reports Q3 2026 Results; Net Loss Widens to $6.1M on Higher R&D Spend

Tvardi Therapeutics reported a Q3 2026 net loss of $6.1 million compared to a net loss of $5.5 million in Q3 2025, as R&D expenses increased to $4.5 million from $3.6 million driven by higher clinical costs for TTI-101. Basic and diluted net loss per share improved to $(0.48) from $(0.59) year-over-year. The company ended Q3 2026 with $22.3 million in cash and cash equivalents, down from $30.8 million at year-end 2025, and expects this to fund operations into Q3 2027.

Share this story

Key takeaways

  • Net loss widened to $6.1 million in Q3 2026 versus $5.5 million in Q3 2025, driven by increased R&D spending on TTI-101 clinical trials.

  • Basic and diluted EPS improved to $(0.48) from $(0.59) year-over-year due to higher share count from equity financings.

  • Cash position declined to $22.3 million as of September 30, 2026, from $30.8 million at December 31, 2025, with runway expected into Q3 2027.

  • TTI-109 ulcerative colitis program advancing toward IND filing and Phase 1 trial initiation in 2027, subject to regulatory clearance and additional funding.

  • TTI-101 hepatocellular carcinoma Phase 1b/2 REVERT LIVER CANCER study on track for topline data in early Q1 2027.

  • Nine-month net loss widened to $19.4 million from $10.9 million in the prior-year period, partly due to $7.2 million other income recorded in Q1 2025.

Key metrics

Net lossQ3 2026 (three months ended September 30, 2026)
$6.1 millionworsened from $5.5 million
Net loss (nine months)Nine months ended September 30, 2026
$19.4 millionworsened from $10.9 million
Basic net loss per shareQ3 2026
$(0.48)improved from $(0.59)
Diluted net loss per shareQ3 2026
$(0.48)improved from $(0.59)
Basic net loss per share (nine months)Nine months ended September 30, 2026
$(1.85)worsened from $(1.62)
Cash and cash equivalentsAs of September 30, 2026
$22.3 milliondown from $30.8 million (cash, cash equivalents and short-term investments as of December 31, 2025)
Research and development expensesQ3 2026
$4.5 millionup from $3.6 million
General and administrative expensesQ3 2026
$1.9 milliondown from $2.3 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow TVRD in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert